MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Has $5.08 Million Position in Insulet Co. (NASDAQ:PODD)

MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. decreased its stake in Insulet Co. (NASDAQ:PODD - Free Report) by 16.5% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 19,469 shares of the medical instruments supplier's stock after selling 3,852 shares during the quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.'s holdings in Insulet were worth $5,083,000 at the end of the most recent quarter.

A number of other large investors have also recently bought and sold shares of PODD. Norges Bank acquired a new stake in shares of Insulet in the 4th quarter valued at $248,806,000. Raymond James Financial Inc. acquired a new position in Insulet in the fourth quarter valued at about $69,433,000. Alecta Tjanstepension Omsesidigt acquired a new position in Insulet in the fourth quarter valued at about $53,184,000. Artisan Partners Limited Partnership grew its stake in Insulet by 24.1% during the fourth quarter. Artisan Partners Limited Partnership now owns 770,188 shares of the medical instruments supplier's stock worth $201,073,000 after buying an additional 149,524 shares during the last quarter. Finally, Northern Trust Corp increased its holdings in shares of Insulet by 20.5% during the fourth quarter. Northern Trust Corp now owns 738,811 shares of the medical instruments supplier's stock worth $192,881,000 after buying an additional 125,710 shares in the last quarter.

Wall Street Analyst Weigh In

PODD has been the topic of a number of research analyst reports. Oppenheimer increased their price target on Insulet from $312.00 to $324.00 and gave the stock an "outperform" rating in a research report on Friday, May 9th. Raymond James reissued an "outperform" rating and issued a $328.00 price objective (up previously from $294.00) on shares of Insulet in a research note on Friday, February 21st. Wells Fargo & Company set a $322.00 target price on Insulet in a research note on Monday, April 28th. Wall Street Zen downgraded shares of Insulet from a "buy" rating to a "hold" rating in a research report on Thursday. Finally, Royal Bank of Canada initiated coverage on shares of Insulet in a report on Thursday, March 6th. They set an "outperform" rating and a $340.00 price objective on the stock. Four equities research analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $308.00.

Insider Transactions at Insulet

In related news, SVP John W. Kapples sold 5,278 shares of the stock in a transaction that occurred on Wednesday, May 14th. The shares were sold at an average price of $318.47, for a total value of $1,680,884.66. Following the sale, the senior vice president now directly owns 23,180 shares in the company, valued at $7,382,134.60. This trade represents a 18.55% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Wayne A.I. Frederick sold 1,825 shares of the business's stock in a transaction that occurred on Tuesday, March 25th. The shares were sold at an average price of $275.00, for a total transaction of $501,875.00. Following the transaction, the director now owns 3,231 shares of the company's stock, valued at approximately $888,525. This represents a 36.10% decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 0.39% of the company's stock.

Insulet Trading Down 1.1%

PODD traded down $3.50 during trading on Thursday, reaching $321.00. 991,446 shares of the company's stock were exchanged, compared to its average volume of 708,855. The company's fifty day moving average price is $268.73 and its 200-day moving average price is $268.38. The firm has a market capitalization of $22.59 billion, a PE ratio of 55.44, a P/E/G ratio of 3.62 and a beta of 1.26. Insulet Co. has a fifty-two week low of $170.67 and a fifty-two week high of $329.33. The company has a debt-to-equity ratio of 1.21, a quick ratio of 2.80 and a current ratio of 3.68.

Insulet (NASDAQ:PODD - Get Free Report) last posted its quarterly earnings results on Thursday, May 8th. The medical instruments supplier reported $1.02 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.81 by $0.21. Insulet had a return on equity of 24.46% and a net margin of 20.19%. The business had revenue of $569.00 million for the quarter, compared to analyst estimates of $543.20 million. During the same period last year, the company earned $0.73 EPS. The firm's revenue was up 28.8% on a year-over-year basis. As a group, equities analysts forecast that Insulet Co. will post 3.92 EPS for the current year.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.